Lemur tyrosine kinase 3 (LMTK3) is associated with cell proliferation and endocrine resistance in breast cancer. Now, a team of researchers from the University of Sussex has completed a five-year study that provides evidence for a potential new target for breast cancer treatment. It suggests that LMTK3 inhibitors could be effectively used for the treatment of breast cancer, and potentially other types of cancer.
Their five-year study, “The structure-function relationship of oncogenic LMTK3,” is published in Science Advances, involved researchers from seven institutions across three countries including the U.K.’s Diamond Light Source.